These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 18083385)

  • 1. Cardiac toxicity of sunitinib.
    Joensuu H
    Lancet; 2007 Dec; 370(9604):1978-80. PubMed ID: 18083385
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ
    J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 4. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
    Arnaud L; Schartz NE; Bousquet G; Sarandi F; Verola O; Madelaine I; Kerob D; Lebbe C
    J Clin Oncol; 2008 Mar; 26(9):1569-71. PubMed ID: 18349416
    [No Abstract]   [Full Text] [Related]  

  • 5. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
    Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
    [No Abstract]   [Full Text] [Related]  

  • 6. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.
    Khakoo AY; Kassiotis CM; Tannir N; Plana JC; Halushka M; Bickford C; Trent J; Champion JC; Durand JB; Lenihan DJ
    Cancer; 2008 Jun; 112(11):2500-8. PubMed ID: 18386829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
    Ewer MS; Suter TM; Lenihan DJ; Niculescu L; Breazna A; Demetri GD; Motzer RJ
    Eur J Cancer; 2014 Aug; 50(12):2162-70. PubMed ID: 24930624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
    Miksad RA; Lai KC; Stein MC; Healy ME; Rojas R; Krajewski KM; Zhu AX
    J Gastrointest Cancer; 2009; 40(3-4):119-22. PubMed ID: 19894033
    [No Abstract]   [Full Text] [Related]  

  • 9. Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
    Garfield D; Hercbergs A; Davis P
    Nat Clin Pract Oncol; 2007 Dec; 4(12):674. PubMed ID: 17955044
    [No Abstract]   [Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors and acute pancreatitis.
    Pezzilli R; Corinaldesi R; Morselli-Labate AM
    JOP; 2010 May; 11(3):291-3. PubMed ID: 20442535
    [No Abstract]   [Full Text] [Related]  

  • 11. Lung toxicity in a patient treated with sunitinib.
    Boyle HJ; Chatté G; Rivoire M; Fléchon A
    Eur Respir J; 2012 Nov; 40(5):1300-3. PubMed ID: 23115316
    [No Abstract]   [Full Text] [Related]  

  • 12. Scrotal cutaneous toxicity: an uncommon but important side-effect of sunitinib.
    Gupta V; Rao A; Gupta S
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):132-3. PubMed ID: 25060046
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
    van der Veldt AA; van den Eertwegh AJ; Boven E
    Ned Tijdschr Geneeskd; 2007 May; 151(20):1142-7. PubMed ID: 17557672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute cardiac failure after sunitinib.
    Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
    Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
    [No Abstract]   [Full Text] [Related]  

  • 15. [New drugs; sunitinib and sorafenib].
    van Bronswijk H; Dubois EA; Osanto S; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home blood-pressure monitoring in patients receiving sunitinib.
    Azizi M; Chedid A; Oudard S
    N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment.
    Fountas A; Tigas S; Giotaki Z; Petrakis D; Pentheroudakis G; Tsatsoulis A
    Hormones (Athens); 2015; 14(3):438-41. PubMed ID: 25553766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eccrine squamous syringometaplasia associated with sunitinib therapy.
    Sheen YS; Huang CL; Chu CY
    J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1136-7. PubMed ID: 17714156
    [No Abstract]   [Full Text] [Related]  

  • 20. Scrotal cutaneous side effects of sunitinib.
    Billemont B; Barete S; Rixe O
    N Engl J Med; 2008 Aug; 359(9):975-6; discussion 976. PubMed ID: 18753659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.